Inhibitors of neutral endopeptidase/CALLA as chemotherapeutic agents
AssigneeBoard of Regents, The University of Texas
InventorsLouis B. Hersh, R. C. Bateman, Jr.
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to inhibitors of neutral endopeptidase (NEP) which are proposed as novel agents for the treatment of CALLA+ positive cancers as well as other conditions such as hypertension.
Claims35
A method of inhibiting the growth or differentiation of CALLA+ human leukemia cells comprising subjecting such cells to an effective amount of an NEP inhibitor.
An NEP inhibitor comprising BADLG, or a derivative thereof, wherein alanine or beta-alanine is substituted for glycine.
An NEP inhibitor which comprises the formula:
- ##STR28## wherein:
- X=--CH.sub.2 --.phi., isopropyl or isobutyl,
- or a derivative or analog thereof.
An NEP inhibitor having the formula:
- ##STR29##
An NEP inhibitor having the formula:
- ##STR30## wherein:
- S1=benzyl, isobutyl, or their analogs;
- and
- S2=Ala, .beta.-Ala, gly or their analogs.
An NEP inhibitor having the formula:
- ##STR32## wherein:
- S1=benzyl, isobutyl, or their analogs;
- and
- S2=Ala, .beta.-Ala, gly or their analogs.
An NEP inhibitor having the formula:
- ##STR35##
Dependencies are inferred from the claim text.